BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shoji S, Nakano M, Sato H, Tang XY, Osamura YR, Terachi T, Uchida T, Takeya K. The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis 2014;31:111-34. [PMID: 23959576 DOI: 10.1007/s10585-013-9612-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Rabjerg M, Guerra B, Oliván-Viguera A, Mikkelsen ML, Köhler R, Issinger OG, Marcussen N. Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma. Oncotarget 2017;8:1613-27. [PMID: 27906674 DOI: 10.18632/oncotarget.13693] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
2 Zhao Q, Guo J, Wang G, Chu Y, Hu X. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Oncotarget 2017;8:1668-77. [PMID: 27926489 DOI: 10.18632/oncotarget.13774] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
3 Violette PD, Kamel-Reid S, Graham GE, Reaume MN, Jewett MA, Care M, Basiuk J, Pautler SE. Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. Can Urol Assoc J 2014;8:E832-40. [PMID: 25485012 DOI: 10.5489/cuaj.2415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol 2015;8:16. [PMID: 25886184 DOI: 10.1186/s13045-015-0113-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
5 Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. Cancer Biol Ther 2017;18:863-71. [PMID: 27715452 DOI: 10.1080/15384047.2016.1219816] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
6 Sleeman JP. Introduction of revised "Aims and Scope" for Clinical & Experimental Metastasis. Clin Exp Metastasis 2016;33:741-2. [PMID: 27678280 DOI: 10.1007/s10585-016-9823-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Czarnecka AM, Kukwa W, Kornakiewicz A, Lian F, Szczylik C. Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. Future Oncology 2014;10:2493-508. [DOI: 10.2217/fon.14.162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, Kowalczyk AE, Grzegrzolka J, Godlewski J, Kwiatkowski P, Dziegiel P, Kmiec Z. Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome. Cancer Genomics Proteomics 2019;16:179-93. [PMID: 31018949 DOI: 10.21873/cgp.20124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ciccarese C, Modena A, Tortora G, Massari F. Kidney cancer and 2014: is innovation really over? Future Oncology 2015;11:1437-49. [DOI: 10.2217/fon.15.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Ramchandani D, Weber GF. Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer. Biochim Biophys Acta 2015;1855:202-22. [PMID: 25732057 DOI: 10.1016/j.bbcan.2015.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
11 Qi C, Ma H, Zhang HT, Gao JD, Xu Y. Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma. Histopathology 2015;66:650-7. [PMID: 25322808 DOI: 10.1111/his.12587] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
12 Vilaseca A, Nguyen DP, Vertosick EA, Corradi RB, Musquera M, Pérez M, Fossati N, Sjoberg DD, Farré R, Almendros I, Montserrat JM, Benfante NE, Hakimi AA, Skanderup AJ, Russo P, Alcaraz A, Touijer KA. Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World J Urol 2017;35:51-6. [PMID: 27108420 DOI: 10.1007/s00345-016-1830-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Xie M, He CS, Huang JK, Lin QZ. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial. European Journal of Cancer 2015;51:595-603. [DOI: 10.1016/j.ejca.2015.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Mol Clin Oncol 2014;2:1023-7. [PMID: 25279192 DOI: 10.3892/mco.2014.360] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]